Join BIOCYTOGEN at AET (Antibody Engineering & Therapeutics) US 2024
We’re thrilled to announce our participation as an exhibitor at AET (Antibody Engineering & Therapeutics) US 2024! From December 15th to 18th in San Diego, California, this premier event will bring together leading minds in life sciences for insight exchange, collaboration, and advancement. Unlock the opportunity to be part of discussions on breakthrough topics like bispecifics, ADCs, antibody-based therapies for cancer and neurodegenerative diseases, and much more. Join us as we explore the future of antibody engineering and therapeutics!
What is AET (Antibody Engineering & Therapeutics) US 2024?
The Antibody Engineering & Therapeutics (AET) global conference series unites scientists and industry leaders to advance antibody science, technology, and collaboration. AET aims to accelerate next-generation antibody development for commercial applications, covering a wide array of topics including antibody discovery, engineering, bispecifics, ADCs, immuno-oncology, AI/ML applications, neurodegenerative diseases, and the tumor microenvironment in antibody therapy.
Event Overview
Date: December 15th 9:00 am – 18th 5:50 pm
Venue: Marriott Marquis San Diego
Event Schedule
The AET (Antibody Engineering & Therapeutics) US in San Diego, California will showcase a diverse array of speakers and topics. For a comprehensive look at the daily schedule, including session times and detailed information on each presentation, please refer to the AET (Antibody Engineering & Therapeutics) US 2024 agenda.
About BIOCYTOGEN
Biocytogen is a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies. Founded on gene editing technology, Biocytogen leverages genetically engineered proprietary RenMice® platforms for fully human monoclonal antibody discovery, and has established a sub-brand, RenBiologics™, to explore global partnerships for an off-the-shelf library of >400,000 fully human antibody sequences against approximately 1000 targets for worldwide collaboration. Biocytogen pioneered the generation of drug target knock-in humanized models for preclinical research, and currently provides a few thousand off-the-shelf animal and cell models under the company’s sub-brand, BioMice™, along with preclinical pharmacology and gene-editing services for clients worldwide. Headquartered in Beijing, Biocytogen has branches in China (Haimen Jiangsu, Shanghai), USA(Boston, San Francisco), and Germany (Heidelberg).
We look forward to seeing you at the AET (Antibody Engineering & Therapeutics) US 2024 in San Diego, California!
